APA (7th ed.) Citation

Azuma, K., Imai, H., Yamaguchi, T., Kijima, T., Kishi, K., Fujita, K., . . . Horinouchi, H. (2024). MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC. Annals of Oncology, 35, S1328. https://doi.org/10.1016/j.annonc.2024.07.515

Chicago Style (17th ed.) Citation

Azuma, K., et al. "MO1-2 Safety Profile of LIGHT-NING 3rd Interim Analysis: 1L Nivolumab + Ipilimumab +/− Chemotherapy for Metastatic NSCLC." Annals of Oncology 35 (2024): S1328. https://doi.org/10.1016/j.annonc.2024.07.515.

MLA (9th ed.) Citation

Azuma, K., et al. "MO1-2 Safety Profile of LIGHT-NING 3rd Interim Analysis: 1L Nivolumab + Ipilimumab +/− Chemotherapy for Metastatic NSCLC." Annals of Oncology, vol. 35, 2024, p. S1328, https://doi.org/10.1016/j.annonc.2024.07.515.